Self-assemblies of 5′-cholesteryl-ethyl-phosphoryl zidovudine

Du, Lina; Jia, Junjie; Ge, Pingju; Jin, Yiguang

doi:10.1016/j.colsurfb.2016.09.009

Cited by 9 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prodrugs are bioreversible derivatives of drug molecules that are generally inactive but can be transformed into their active forms via chemical or enzyme-catalyzed reactions 141 . The prodrug nanomedicines (PNs) based on the molecular self-assembly of amphiphilic prodrugs were developed decades ago142, 143. They were named as self-assembled drug delivery systems (SADDS), prodrug self-assemblies, or nanodrugs.…”

Section: Emerging Techniques For Drug Deliverymentioning

confidence: 99%

“…4). Anticancer and antiviral drugs are commonly used parent drugs for PN design142, 144, 145, 146, 147. For example, the anti-cancer prodrugs paclitaxel and gemcitabine have been widely studied due to their higher loading efficiency, stimuli-responsive drug release and enhanced therapeutic efficiency144, 148, 149, 150.…”

Section: Emerging Techniques For Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Recent progress in drug delivery

Wang

et al. 2019

Acta Pharmaceutica Sinica B

Self Cite

616

272

View full text Add to dashboard Cite

Drug delivery systems (DDS) are defined as methods by which drugs are delivered to desired tissues, organs, cells and subcellular organs for drug release and absorption through a variety of drug carriers. Its usual purpose to improve the pharmacological activities of therapeutic drugs and to overcome problems such as limited solubility, drug aggregation, low bioavailability, poor biodistribution, lack of selectivity, or to reduce the side effects of therapeutic drugs. During 2015–2018, significant progress in the research on drug delivery systems has been achieved along with advances in related fields, such as pharmaceutical sciences, material sciences and biomedical sciences. This review provides a concise overview of current progress in this research area through its focus on the delivery strategies, construction techniques and specific examples. It is a valuable reference for pharmaceutical scientists who want to learn more about the design of drug delivery systems.

show abstract

Section: Emerging Techniques For Drug Deliverymentioning

confidence: 99%

Section: Emerging Techniques For Drug Deliverymentioning

confidence: 99%

Recent progress in drug delivery

Wang

et al. 2019

Acta Pharmaceutica Sinica B

Self Cite

616

272

View full text Add to dashboard Cite

show abstract

“…According to the WHO global health survey, there are 38.0 million people living with HIV, and 690,000 people had died by the year 2021 [43]. There is no specific vaccine or medicine available to cure AIDS, but there are some natural and synthetic drug candidates available [44,45]. Dolutegravir, sold under the brand name of Tivicay, was the bestselling anti-HIV drug in 2018 [46].…”

Section: Human Immunodeficiency Virus (Hiv)mentioning

confidence: 99%

Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities

Manna,

Das,

Santra

et al. 2023

Viruses

View full text Add to dashboard Cite

Antiviral properties of different oxa- and aza-heterocycles are identified and properly correlated with their structural features and discussed in this review article. The primary objective is to explore the activity of such ring systems as antiviral agents, as well as their synthetic routes and biological significance. Eventually, the structure–activity relationship (SAR) of the heterocyclic compounds, along with their salient characteristics are exhibited to build a suitable platform for medicinal chemists and biotechnologists. The synergistic conclusions are extremely important for the introduction of a newer tool for the future drug discovery program.

show abstract

Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids

Zhou

Wang

Zhu

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

With the rapid development of synthetic technology and biological technology, many nucleic acid‐based drugs have entered the clinical trials. However, their inherent disabilities in actively and efficiently penetrating cell membranes still severely restrict their further application. The main drawback of cationic lipids, which have been widely used as nonviral vectors of nucleic acids, is their high cytotoxicity. A series of nucleoside‐based or nucleotide‐based nucleolipids have been reported in recent years, due to their oligonucleotide delivery capacity and low toxicity in comparison with cationic lipids. Lipophilic prodrugs of nucleoside analogs have extremely similar structures with nucleolipid vectors and are thus helpful for improving the transmembrane ability. This review introduces the progress of nucleolipids and provides new strategies for improving the delivery efficiency of nucleic acid‐based drugs, as well as lipophilic prodrugs of nucleosides or nucleotides for antiviral or anticancer therapies.

show abstract

Self-assemblies of 5′-cholesteryl-ethyl-phosphoryl zidovudine

Cited by 9 publications

References 37 publications

Recent progress in drug delivery

Recent progress in drug delivery

Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities

Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids

Contact Info

Product

Resources

About